News

New recommendations for the classification of variants in the POLE and POLD1 genes to improve diagnostic accuracy in hereditary cancer

The group has applied these classification recommendations to 128 variants reported in the literature and/or public databases, classifying 17 as pathogenic variants, and another 17 as benign.

Leer más about New recommendations for the classification of variants in the POLE and POLD1 genes to improve diagnostic accuracy in hereditary cancer

Absolute success of the Sinergia 2023 open day

This Saturday took place the open day of the fifth edition of Sinergia, the celebration of health research and innovation in L’Hospitalet. More than 300 people came to the Bellvitge Campus to take part in the everyday work of that IDIBELL, the Catalan Institute of Oncology, the Bellvitge University Hospital, the University of Barcelona and the Hospital Sant Joan de Déu do to improve people’s health.

Leer más about Absolute success of the Sinergia 2023 open day

The Mediterranean diet and olive oil may benefit the prevention of some types of cancers related to obesity

A new study carried out by the Nutrition and Cancer research group of IDIBELL and the Catalan Institute of Oncology, with the collaboration of the scientific and technological center AZTI, offers a relevant review and update of data that demonstrates how eating habits and the microbiota intestine could play a key role in cancer prevention.

Leer más about The Mediterranean diet and olive oil may benefit the prevention of some types of cancers related to obesity

Sinergia will open its doors to Bellvitge health research and innovation

On the morning of Saturday, October 21, the 5th edition of Sinergia will bring the science of the Bellvitge Campus closer to citizens.

Leer más about Sinergia will open its doors to Bellvitge health research and innovation

The IDIBELL’s spin-off ADmit therapeutics closes a €5.4 million funding round

ADmit Therapeutics is a biotechnology company founded at the end of 2017 as a spin-off from the Bellvitge Biomedical Research Institute (IDIBELL). The company is focused on the development and commercialization of a new early detection technology for Alzheimer’s disease (AD) and has successfully closed a €5.4 million equity round.

Leer más about The IDIBELL’s spin-off ADmit therapeutics closes a €5.4 million funding round

Research led in Bellvitge will allow progress in the fight against bacteremia

The study has been published in the journal Nature Medicine, one of the most prestigious in Medicine, and represents a step forward to address an important health challenge worldwide, with high rates of therapeutic failure and mortality.

Leer más about Research led in Bellvitge will allow progress in the fight against bacteremia
Scroll to Top